

# Cyriel Y Ponsioen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9654928/publications.pdf>

Version: 2024-02-01

87  
papers

7,461  
citations

76294

40  
h-index

54882

84  
g-index

89  
all docs

89  
docs citations

89  
times ranked

7195  
citing authors

#	ARTICLE	IF	CITATIONS
1	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	6.3	257
2	Epigenetic Signatures Discriminate Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis From Patients With Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2022, 13, 840935.	2.2	4
3	Fecal Filobasidium Is Associated with Clinical Remission and Endoscopic Response following Fecal Microbiota Transplantation in Mild-to-Moderate Ulcerative Colitis. <i>Microorganisms</i> , 2022, 10, 737.	1.6	7
4	Symptom patterns in the daily life of <scp>PSC</scp> patients. <i>Liver International</i> , 2022, 42, 1562-1570.	1.9	7
5	Endoscopic vacuum-assisted surgical closure (EVASC) of anastomotic defects after low anterior resection for rectal cancer; lessons learned. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 8280-8289.	1.3	5
6	Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, , .	0.9	2
7	Impaired Quality of Working Life in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2916-2924.	1.1	13
8	Antibiotic Therapy of 3ÂˆDays May Be Sufficient After Biliary Drainage for Acute Cholangitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4128-4139.	1.1	8
9	Expression of MAdCAM-1 and Gut-homing T Cells in Inflamed Pouch Mucosa. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1491-1499.	0.6	5
10	Ustekinumab for Crohnâ€™s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1920-1930.	0.6	22
11	A novel technique capable of taking â€“protectedâ€™ biopsies for reliable assessment of the distribution of microbiota along the colonic mucosa. <i>Journal of Microbiological Methods</i> , 2021, 185, 106204.	0.7	1
12	Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis. <i>Liver International</i> , 2021, 41, 2681-2692.	1.9	7
13	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <i>Gastroenterology</i> , 2021, 161, 1764-1775.e5.	0.6	28
14	Feeding the Gutâ€“Liver Axis in PSC: What Makes It Different from IBD?. <i>Gastroenterology</i> , 2021, 161, 1070-1071.	0.6	0
15	Liver Impairmentâ€“The Potential Application of Volatile Organic Compounds in Hepatology. <i>Metabolites</i> , 2021, 11, 618.	1.3	19
16	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
17	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
18	Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100054.	2.0	10

#	ARTICLE	IF	CITATIONS
19	The Simple Cholestatic Complaints Score is a valid and quick patient-reported outcome measure in primary sclerosing cholangitis. <i>Liver International</i> , 2020, 40, 2758-2766.	1.9	6
20	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
21	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIRIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 900-907.	3.7	75
22	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	2.4	18
23	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
24	Comparison of contrast-enhanced and diffusion-weighted MRI in assessment of the terminal ileum in Crohn's disease patients. <i>Abdominal Radiology</i> , 2019, 44, 398-405.	1.0	3
25	Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 603-615.	1.8	27
26	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
27	Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 281-288.	0.6	24
28	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	1.8	148
29	Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIRIC Trial. <i>Gut</i> , 2019, 68, 1774-1780.	6.1	56
30	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 937-944.	0.9	29
31	Comparison of MRI Activity Scoring Systems and Features for the Terminal Ileum in Patients With Crohn Disease. <i>American Journal of Roentgenology</i> , 2019, 212, W25-W31.	1.0	29
32	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1558-1565.	0.9	7
33	Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2018, 68, 1174-1188.	3.6	42
34	Semiautomatic Assessment of the Terminal Ileum and Colon in Patients with Crohn Disease Using MRI (the VIGOR++ Project). <i>Academic Radiology</i> , 2018, 25, 1038-1045.	1.3	14
35	Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 305-316.	3.7	31
36	Endpoints in the design of clinical trials for primary sclerosing cholangitis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1410-1414.	1.8	4

#	ARTICLE	IF	CITATIONS
37	A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1864-1869.	6.1	81
38	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64
39	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
40	Î2-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 161-166.	0.8	16
41	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
42	Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1438-1447.	0.6	12
43	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2018, 155, 752-759.e5.	0.6	69
44	TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1122-1130.	0.6	25
45	Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. <i>PLoS ONE</i> , 2018, 13, e0190999.	1.1	30
46	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multicentre study. <i>Liver International</i> , 2017, 37, 1554-1561.	1.9	54
47	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
48	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , 2017, 66, 1214-1222.	1.8	51
49	Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. <i>ISME Journal</i> , 2017, 11, 1877-1889.	4.4	157
50	Semi-automatic bowel wall thickness measurements on MR enterography in patients with Crohn's disease. <i>British Journal of Radiology</i> , 2017, 90, 20160654.	1.0	14
51	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , 2017, 49, 588-608.	1.0	154
52	Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1702-1709.	0.9	174
53	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 785-792.	3.7	196
54	Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge. <i>Hepatology International</i> , 2017, 11, 132-140.	1.9	16

#	ARTICLE	IF	CITATIONS
55	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , 2017, 65, 907-919.	3.6	79
56	Effectiveness of cognitive-behavioral therapy on quality of life, anxiety, and depressive symptoms among patients with inflammatory bowel disease: A multicenter randomized controlled trial. <i>Journal of Consulting and Clinical Psychology</i> , 2017, 85, 918-925.	1.6	53
57	Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	11
58	Risk factors for primary sclerosing cholangitis. <i>Liver International</i> , 2016, 36, 84-91.	1.9	24
59	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , 2016, 63, 1357-1367.	3.6	133
60	Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value. <i>Liver International</i> , 2016, 36, 1867-1875.	1.9	70
61	Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1065-1072.	0.8	47
62	MRI characteristics of proctitis in Crohn's disease on perianal MRI. <i>Abdominal Radiology</i> , 2016, 41, 1918-1930.	1.0	15
63	Reply. <i>Gastroenterology</i> , 2016, 150, 286-287.	0.6	1
64	Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 251-258.e2.	2.4	171
65	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 366.	0.7	40
66	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , 2015, 62, 188-197.	3.6	106
67	Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. <i>World Journal of Gastroenterology</i> , 2015, 21, 5359.	1.4	204
68	Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1480-1486.e3.	2.4	55
69	The Mucosa-associated Microbiota of PSC Patients is Characterized by Low Diversity and Low Abundance of Uncultured Clostridiales II. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 342-348.	0.6	106
70	Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 149, 350-355.e2.	0.6	342
71	The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019). <i>BMC Surgery</i> , 2015, 15, 30.	0.6	40
72	Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 149, 110-118.e4.	0.6	769

#	ARTICLE	IF	CITATIONS
73	Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2015, 63, 1212-1219.	1.8	56
74	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
75	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
76	Prior Colorectal Neoplasia Is Associated With Increased Risk of Ileoanal Pouch Neoplasia in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, 119-128.e1.	0.6	113
77	Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. <i>Hepatology</i> , 2014, 59, 1954-1963.	3.6	158
78	Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 881-886.	0.4	22
79	Acute Dysphagia: Don't Wait and See. <i>Gastroenterology</i> , 2014, 147, 281-282.	0.6	2
80	Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: follow-up for up to 36 years. <i>Hepatology International</i> , 2014, 8, 266-74.	1.9	22
81	Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 866-875.	0.6	69
82	Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. <i>Hepatology</i> , 2013, 58, 2045-2055.	3.6	519
83	Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. <i>Journal of Hepatology</i> , 2012, 56, 1181-1188.	1.8	506
84	Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2270-2276.	0.9	202
85	Recent insights in primary sclerosing cholangitis. <i>Journal of Digestive Diseases</i> , 2012, 13, 337-341.	0.7	9
86	A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 522-526.	1.1	109
87	A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved?. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 641-648.	0.8	37